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Abstract
Portopulmonary hypertension is a rare and severe complication of patients with cirrhosis.
Sarcoidosis, a disease of unknown etiology, is also a cause of pulonary hypertension and right heart
dysfunction. We report the case of a 51-year-old male patient, suffering from cirrhosis due to
Wilson’s disease, portal hypertension and pulmonary hypertension (PH), who developed severe
pericarditis. Wilson’s disease was diagnosed 8 years before his last admission to our hospital and was
being successfully treated with D-penicillamine. PH was recognized 2 years before admission and
being treated with bosentan. The patient complained for dyspnea at rest and the 2D echocardiogram
revealed a significant amount of pericardial fluid. All other causes of acute pericarditis were excluded
and his laboratory, imaging and histopathological investigation showed evidence of sarcoidosis.
He underwent a therapy with corticosteroids (methylprednisolone) and his follow-up examination
showed remarkable decrease of the levels of mean pulmonary artery pressure and pericardial fluid.
Introduction
Portopulmonary hypertension (PPHT) is a pulmonary
vascular consequence of advanced liver disease. Some
studies suggest that the frequency of PPHT in cirrhotic
patients is about 6%. The pathogenesis of PPHT is
suggested to be based on an increased flow or volume
phenomenon, secondary to the hyperdynamic circulation
of cirrhosis and vasoconstriction due to an increase in
vasoconstrictive substances entering the pulmonary circu-
lation from the hepato-splanchnic vascular bed, such as
endothelin-1 and others [1].
Pulmonary hypertension (PH) is also a well-known
complication of sarcoidosis. In patients with sarcoidosis
the prevalence of PH and right heart dysfunction has been
reported to range from 4% to 28%. In most cases,
Page 1 of 5
(page number not for citation purposes)sarcoidosis-related PH is mild to moderate or is mani-
fested only with exercise. Severe PH has been described in
sarcoidosis usually in association with severe fibrotic
parenchymal disease. It can also occur in the absence of
pulmonary fibrosis by means of granulomatous vasculitis
of the pulmonary vessels or plexiform pulmonary arterio-
pathy or extrinsic compression of large pulmonary arteries
by mediastinal or hilar adenopathies. Uncommonly,
portal hypertension secondary to liver sarcoidosis can
also induce PH [2,3].
Case presentation
A 51-year-old Caucasian male was admitted to our
department complaining for dyspnea, for about 20 days
before admission, combined with fatigability, without
chest pain, cough, fever or other relative symptoms. He
had been hospitalized in our department because of
jaundice and signs of hepatic failure 8 years ago. At that
time the investigation had led to the diagnosis of Wilson’s
disease. D-penicillamine was administered and the patient
responded impressively. Since then he was being fol-
lowed-up at regular intervals. Six and a half years later, he
was admitted again due to fatigue. He was diagnosed as
having PH on 2D echocardiography and started therapy
with bosentan (firstly 67.5 mg bid and then 125 mg bid)
and sildenafil (25 mg tid and then 50 mg tid). Due to his
clinical and echocardiographic improvement, 3 months
later, he was treated only with bosentan at the same dose
until his last admission.
On physical examination he had peripheral edema,
inflated jugular veins and vascular spiders, a systolic
murmur of the tricuspid valve, elevation of S2 and split of
S2 at the focus of pulmonary valve and splenomegaly. The
electrocardiography revealed right axis deviation and right
bundle branch block. The chest radiograph showed a
“water bottle” configuration of the cardiac silhouette and
ambilateral enlargement of the pulmonary hili, and the
2D echocardiography revealed presence of significant
amount of pericardial fluid, as well as increased dimen-
sionsof rightcavities and mildregurgitation of the tricuspid
valve. The right ventricular systolic pressure (RVSP), as
estimated by echocardiography, was 75-80 mmHg
(normal <25 mmHg).
Laboratorytestingonadmissionrevealedleucopenia(WBC:
3,600/μL) and thrombocytopenia (PLT: 83,000/μL).
Cirrhosis was well compensated: INR: 1.33, albumin:
4.6 g/dL. The other liver function tests were normal, as was
his renal function.
The diagnostic approach to our patient was headed
towards the etiology of pericarditis. Viral markers [Hepa-
titis B and C, Human Immunodeficiency Virus (HIV),
Ebstein-Barr, Herpes Simple, Cytomegalovirus, Echo,
Parvo, Coxsackie and Arbo] as well as investigation for
Mycoplasma Pneumoniae, Chlamydia and Coxsiella
Burnetti, were negative. His autoimmune profile, tumor
markers and thyroid function were normal. Finally, a
tuberculin skin test (Mantoux) was performed, which was
positive (infiltration of 15 mm).
Regardingthepatient’ssituationandthepositiveMantoux-
test, a Computerized Tomography (CT) of the thorax
(Figure 1) and abdomen was performed, which showed,
apart from a significant amount of pericardial fluid,
enlarged lymph nodes of the anterior and right posterior
mediastinum, left hilum, carina and the left part of the
pulmoaortic window. The CT of the abdomen revealed
liver cirrhosis, splenomegaly and dilatation of the portal
and splenic vein. As a result of these, we decided to check
the levels of the serum angiotensin-converting enzyme
(ACE),whichwerehigh:68IU/L(normalrange:0-52IU/L).
The patient’s initial treatment was to decrease the dose of
bosentan until discontinuation (considering that bosen-
tan causes peripheral edemas) but no improvement was
noticed. On the 10th day of hospitalization, pericardio-
centesis was performed. The pericardial fluid was sangui-
neous, about 1,200cc, exudate, with about 100 WBC
(66.1% neutrophils, 21% lymphocytes, 4.8% monocytes
and 8.1% eosinophils) and haematocrit 0.7%. Specimens
of pericardial fluid were obtained for culture [aerobe and
non aerobe microorganisms, as well as Mycobacterium
tuberculosis (Tb)]. All were negative, as was the PCR test
for Tb. The cytological analysis of the pericardial fluid did
not show evidence of malignancy. Finally, no specific
granulomatous inflammation or malignancy was noticed
on pericardial biopsy.
Figure 1. Pericardial fluid (CT of the thorax).
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th day, the patient restarted therapy with
bosentan (67.5 mg bid) and on the 15
th day sildenafil
was added (25 mg bid) in combination with colchicine
(0.5 mg bid). In order to check the liver’s condition,
respectively to Wilson’s disease, the patient underwent a
liver biopsy. On histological examination most of the
portal tracts were enlarged due to fibrosis and inflamma-
tory infiltration, mainly with lymphocytes. Periportal
hepatitis and portal-portal ligation was also seen. In the
parenchyma, a granuloma was revealed, without central
necrosis, with the presence of multinucleated giant cells.
The histological diagnosis was consistent with granulo-
matous hepatitis (Figure 2). Consequently, the diagnosis
was headed towards sarcoidosis. Therefore, a scintiscan
with gallium (Ga
67) was performed, which was indicative
of sarcoidosis.
On the 18
th day, methylprednisolone was administered
(16 mg tid), in combination with bosentan, sildenafil and
colchicine, on the doses mentioned above. D-penicilla-
mine was replaced by zinc acetate, considering that the
role of D-penicillamine in terms of inducing granuloma-
tous hepatitis and generation pericardial fluid was
indefinite. As a result of this, the levels of copper of
24-hoururineweresignificantlyreduced[from700μg/24h
to 90 μg/24h (target during maintenance of zinc therapy
is 50-125 μg/24h)].
One month later, the echocardiograph showed significant
decrease in the amount of pericardial fluid, but unremark-
able reduction of the levels of RVSP, although the patient
was not complaining for dyspnea any more. Nonetheless,
2 months later, he had only a slight quantity of pericardial
fluid and the estimated RVSP was 40-45 mmHg.
Furthermore, there was also a decrease in the levels of
the serum ACE on the 6-month-follow-up down to 31 IU/
L. In the following months the dose of methylpredniso-
lone was tapered to 24 mg per day and 1 year later (after 2
relapses of pericardial infusion successfully treated with an
increase of methylprednisolone to 32 mg per day with
gradual tapering), he is being treated in a maintenance
dose of 16 mg per day in combination with bosentan 125
mg bid and sindenafil 25 mg bid. The mean pulmonary
arterial pressure (MPAP) performed on right heart
catheterization on 1-year-follow-up in another hospital
was 60-70 mmHg.
Discussion
Cardiac sarcoidosis is often overlooked because of its
subclinical disease progression. Approximately 30% of
patients with systemic sarcoidosis have granulomas in the
myocardium and 5% have sings of cardiac affection. The
pericardium can be involved in sarcoidosis with and
without clinically evident myocardial involvement. Man-
ifestations of pericardial sarcoidosis include symptomatic
or asymptomatic pericardial effusion, with or without
cardiac tamponade, and chronic constrictive pericarditis.
Sarcoidosis of the pericardium has a good prognosis in the
absence of clinically detectable myocardial involvement
[4].
Although corticosteroids remain the mainstay of treat-
ment, there is little evidence for the optimal initiation,
dosage or duration of therapy. Doses of 60-80 mg of
prednisone daily are generally prescribed initially. In some
studies, the starting dose of 30 mg/day was proven
sufficient to improve prognosis. Patients should be re-
evaluated after 2-3 months, and if the disease is respond-
ing, the dose must be tapered gradually to a maintenance
level of 10-15 mg per day over a period of six months. If
serial evaluations reveal that the disease is controlled,
corticosteroids may be tapered further and eventually
discontinued. Prerequisites for steroid taper or withdrawal
include absence of disease activity, confirmed by radio-
nuclide imaging and by serum determinations of ACE if
values were initially elevated at time of diagnosis.
Alternative agents such as antimalarials, methotrexate
and azathioprine may be given to patients who do not
respond to corticosteroids or who cannot tolerate their
side effects [5-7].
In addition, the patient’s positive Mantoux test and
mediastinal lymphadenopathy set Tb in terms of differ-
ential diagnosis. However, there was much more evidence
towards sarcoidosis, (regarding especially the patient’s
liver biopsy and the negative PCR test for Tb), which
forced us to initiate corticosteroid therapy. The long term
administration of methylprednisolone did not induce
manifestation of Tb.
Figure 2. Hepatic parenchyma with the presence of a non
caseating granuloma (arrow) (AEx100).
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endothelinreceptorantagonist,whichhasbeenshowntobe
beneficialinthetreatmentofprimarypulmonaryhyperten-
sion, but its efficacy in secondary pulmonary arterial
hypertension (SPAH) has not been established. SPAH is
anadverseoutcomeofavarietyofsystemicdisorderssuchas
collagen vascular diseases, chronic thromboembolism,
human immunodeficiency virus, portopulmonary hyper-
tension, sarcoidosis and other diseases [8,9].
In the literature there are few published case reports
showing the safety and efficacy of bosentan in patients
with PPHT. Our cirrhotic patient was initially treated
successfully with bosentan for about one year before his
last admission. One potential explanation for the effec-
tiveness of bosentan insuch cases derives fromthefact that
increased hepatic expression of endothelin with hepatos-
plachnic spillover is one putative mechanism for the
development of portopulmonary hypertension [10,11].
It must also be mentioned that D-penicillamine is a very
rare cause of drug-induced granulomatous hepatitis (GH).
We culled only one case report from the literature [12]. GH
has been attributed to a variety of drugs such as:
allopurinol, aspirin, diazepam, isoniazide, phenitoin and
sulphonamides. Other causes of GH incude tuberculosis
(the commonest), sarcoidosis, leprosy, histoplasmosis,
brucellosis, lymphoma and malignant granuloma
[13,14]. The associated lesions of liver injury suggesting a
drug etiology include significant tissue eosinophilia.
Eosinophils are rare to absent in tuberculous hepatic
granulomas and, when present in significant numbers,
militate strongly against sarcoidosis [15,16]. No eosino-
phils were described in our patient’s biopsy. To the best of
our knowledge, the co-existence of Wilson’s disease has
never been reported in the literature. Furthermore,
pericardial effusion along with PH has a very poor
prognosis [17-19] and has been described in few condi-
tions, except for sarcoidosis, such as sickle cell disease [19],
HIV infection [20], primary Sjögren's syndrome (usually
with primary biliary cirrhosis and cryoglobulinemia) [21],
systemic sclerosis [22], systemic lupus erythematosus [23],
Behcet's disease [24]. Pericardiocentesis and percutaneous
balloon pericardiotomy appear to be a reasonable ther-
apeutic approach, although it is characterized by high
mortality [18].
Conclusion
In conclusion, we described a patient who, until his last
admission to out department, was thought to suffer from
SPAH, induced only by liver cirrhosis due to Wilson’s
disease. His further investigation on occasion of acute
pericarditis provided evidence of sarcoidosis, as another
factor for SPAH. This was indicated by his rapid improve-
ment with corticosteroids, respectively to pericarditis, on
the one-month follow-up visit, and by the gradual
decrease in the levels of mean pulmonary arterial pressure,
on the three-month follow up visit. We also hypothesize
that the combination of bosentan with sildenafil led to
further improvement of pulmonary hypertension.
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